Sangamo Therapeutics (SGMO) Q4 2024 earnings summary

Executive summary

• Advanced neurology pipeline with IND clearance for ST-503 in iSFN and nonclinical proof of concept in prion disease, with clinical milestones expected in 2025–2026.

• Fabry gene therapy program (isaralgagene civaparvovec) shows sustained clinical benefit, best-in-class data, and is on an accelerated approval pathway with a BLA submission targeted for H2 2025.

• Secured major pharma collaborations, including Astellas and Genentech, for neurotropic capsids, raising over $100 million in 2024 through non-dilutive fees, milestones, and equity financing.

• Regained full rights to hemophilia A gene therapy after Pfizer terminated the partnership; seeking new collaborators.

• Focus remains on securing a Fabry commercial partner and addressing financial needs to support ongoing programs.

Financial highlights

• Non-GAAP operating expenses reduced by ~45% year-over-year; 2025 OpEx expected to be $125–$145 million (non-GAAP) or $135–$155 million (GAAP).

• Over $100 million raised in 2024 via non-dilutive license fees, milestone payments, and equity financing.

• Q4 2024 net loss was $23.4 million ($0.11/share), improved from $60.3 million ($0.34/share) in Q4 2023; full-year 2024 net loss was $97.9 million ($0.49/share), down from $257.8 million ($1.48/share) in 2023.

• Cash and equivalents at year-end 2024 were $41.9 million, with $10.1 million raised in 2025 and $5 million expected from Pfizer, funding operations into mid-Q2 2025.

• Q4 2024 revenue rose to $7.6 million from $2.0 million in Q4 2023, mainly from Astellas and Genentech agreements.

Outlook and guidance

• Anticipated Fabry partnership in Q2 2025 to provide capital for further program execution.

• Patient enrollment and dosing for ST-503 expected mid-2025, with preliminary efficacy data in Q4 2026.

• Prion disease clinical trial authorization submission planned for Q1 2026, with dosing mid-2026 and data in Q4 2026.

• Fabry BLA submission targeted for H2 2025, with potential commercialization as early as H2 2026.

• Operating expenses for 2025 guided to remain at 2024 levels, focused on neurology pipeline advancement.